World's Best Scientists 2026 revealed!
Award Badge
Medicine
France
2023

D-Index & Metrics

Medicine

D-Index
133
Citations
92667
World Ranking
2179
National Ranking
58

Research.com Recognitions

  • 2023 - Research.com Medicine in France Leader Award

Overview

Karim Fizazi is affiliated with the University of Paris-Saclay in France and specializes primarily in medical research with a strong focus on oncology and related fields.

The research contributions cover several main topics, including:

  • Prostate Cancer Treatment and Research
  • Radiopharmaceutical Chemistry and Applications
  • PARP inhibition in cancer therapy
  • Cancer, Lipids, and Metabolism
  • Prostate Cancer Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Cancer Treatment and Pharmacology

Fizazi's publications span multiple subfields of study, notably:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Radiology, Nuclear Medicine and Imaging
  • Cancer Research
  • Molecular Biology

The frequent publication venues for this scientist include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Urology
  • European Journal of Cancer
  • Cancer Research

Karim Fizazi has collaborated extensively with several co-authors, among whom are:

  • Neal D. Shore
  • Johann S. de Bono
  • Fred Saad
  • Bertrand Tombal
  • Nobuaki Matsubara

Significant recent papers associated with Fizazi's work include:

  • Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design, 2022, The Lancet
  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer, 2021, New England Journal of Medicine
  • Olaparib for Metastatic Castration-Resistant Prostate Cancer, 2020, New England Journal of Medicine
  • Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2020, Annals of Oncology
  • Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer, 2020, New England Journal of Medicine

Best Publications

  • Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    Howard I. Scher;Karim Fizazi;Fred Saad;Mary-Ellen Taplin

  • Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Johann S. de Bono;Christopher J. Logothetis;Arturo Molina;Karim Fizazi

  • Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    Tomasz M Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot

  • Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina

  • Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

    Karim Fizazi;Michael Carducci;Matthew Smith;Ronaldo Damião

  • Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

    Karim Fizazi;Nam Phuong Tran;Luis Fein;Nobuaki Matsubara

  • Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

    Eugene D. Kwon;Charles G. Drake;Howard I. Scher;Karim Fizazi

  • Olaparib for metastatic castration-resistant prostate cancer

    Johann de Bono;Joaquin Mateo;Karim Fizazi;Fred Saad

  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

    Oliver Sartor;Johann de Bono;Kim N Chi;Karim Fizazi

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

    Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis

  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad

  • Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer

    Maha Hussain;Karim Fizazi;Fred Saad;Per Rathenborg

  • Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer : results of a phase 3, randomised, placebo-controlled trial.

    Matthew R Smith;Fred Saad;Robert Coleman;Neal Shore

  • Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

    Tomasz M. Beer;Eugene D. Kwon;Charles G. Drake;Karim Fizazi

  • Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

    F. Saad;J. E. Brown;C. Van Poznak;T. Ibrahim

  • Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

    Karim Fizazi;Neal Shore;Teuvo L. Tammela;Albertas Ulys

  • Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

    Gwenaelle Gravis;Karim Fizazi;Florence Joly;Stéphane Oudard

  • European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I

    Susanne Krege;Jörg Beyer;Rainer Souchon;Peter Albers

  • EAU Guidelines on testicular cancer, 2011 update

    P. Albers;W. Albrecht;F. Algaba;C. Bokemeyer

Frequent Co-Authors

Yohann Loriot
Yohann Loriot University of Paris-Saclay
Fred Saad
Fred Saad University of Montreal
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Neal D. Shore
Neal D. Shore Carolina Urologic Research Center
Laurence Albiges
Laurence Albiges Institut Gustave Roussy
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Cora N. Sternberg
Cora N. Sternberg Cornell University
Matthew R. Smith
Matthew R. Smith Harvard University
Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Kim N. Chi
Kim N. Chi BC Cancer Agency

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens the door to a wide range of online degrees and specialized career pathways. Many healthcare professionals seek advanced qualifications to expand their expertise or move up the career ladder.

For those aiming for the pinnacle of nursing practice, pursuing dnp online programs offers flexibility and the chance to earn a top-level degree without pausing your career. Similarly, aspiring nurses can boost their credentials more quickly through lpn programs that fast-track entry into the nursing field.

Mental health is a growing focus in medicine, and the demand for qualified professionals is high. The online pmhnp programs allow registered nurses to specialize further and fill essential roles as psychiatric mental health nurse practitioners.

Not all medical careers require direct patient care. For those drawn to the business side of healthcare, earning an online healthcare administration degree can lead to leadership roles in hospitals, clinics, and other care settings.

Best Scientists Citing Karim Fizazi

Trending Scientists

Recently Published Articles